UNSPSC 51281816: Daunorubicin aglycone

This classification denotes an anthracycline antibiotic with the molecular formula C21H18O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FN5680X78X, chemically known as 5,12-naphthacenedione, 8-acetyl-7,8,9,10-tetrahydro-6,8,10,11-tetrahydroxy-1-methoxy-, (8s,10s)-, but more generally known as daunorubicin aglycone, which bears US NIH Compound Identifier 83843. European Medicines Agency schedules daunorubicin aglycone or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06917MIG.

Most nations, for tariff purposes, schedule daunorubicin aglycone under HS 29419000. SMILES: CC(=O)[C@@]1(CC2C(C(C3C(C2O)C(=O)C4CCCC(C4C3=O)OC)O)[C@H](C1)O)O.

UNSPSC 51281816 Daunorubicin aglycone is a Commodity code that does not align with the state and local procurement opportunities currently tagged under it. The recent solicitations captured—naloxone and drug deactivation systems for Seminole County, Florida; a direct-to-manufacturer pharmaceutical program inquiry by Texas HHS; medical and first aid supplies for the Tampa Fire Department; and generic multi-source pharmaceuticals through the Minnesota Multistate Cooperative Purchasing Alliance—concern emergency medical supplies, over-the-counter products, and broad pharmaceutical procurement vehicles, not daunorubicin aglycone, which is a specific oncology pharmaceutical. The code shows a significant mismatch between its nominal scope and the work actually being procured under its tag.

State and local agencies purchasing pharmaceutical products do so through emergency-medical-supply bids (city-level), direct RFIs on alternative pharmacy delivery models (state health commissions), and cooperative purchasing vehicles for generic and OTC products (multistate purchasing alliances). Issuing bodies include city fire and rescue departments, state health and human services commissions, and cooperative purchasing organizations serving multiple jurisdictions. Geographic activity captured spans Florida, Texas, and Minnesota, though the opportunities reflect established procurement pathways (competitive bidding, RFIs, cooperative RFPs) rather than concentration in specific jurisdictions or regions. The mismatch between the code's name and the actual procurement activity tagged to it suggests either data-entry error at the issuing body or systematic miscoding—either way, the code itself offers limited signal for pursuing daunorubicin or related oncology pharmaceutical opportunities through state and local channels.